Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy

iOMEDICO AG1 site in 1 country1,500 target enrollmentDecember 2007

ConditionsRenal Cell Carcinoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Renal Cell Carcinoma
Sponsor: iOMEDICO AG
Enrollment: 1500
Locations: 1
Primary Endpoint: Documentation of therapies
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.

Detailed Description

The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Registry

clinicaltrials.gov

Start Date

December 2007

End Date

May 15, 2020

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

iOMEDICO AG

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy
•Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment